↓ Skip to main content

The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy

Overview of attention for article published in Inflammopharmacology, September 2010
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (89th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

patent
55 patents
facebook
10 Facebook pages
wikipedia
1 Wikipedia page

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
68 Mendeley
connotea
1 Connotea
Title
The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy
Published in
Inflammopharmacology, September 2010
DOI 10.1007/s10787-010-0054-4
Pubmed ID
Authors

Peter O. Behan, Abhijit Chaudhuri

Abstract

The literature for evidence of autoimmunity in multiple sclerosis (MS) is analysed critically. In contrast to the accepted theory, the human counterpart of the animal model experimental autoimmune demyelinating disease, experimental allergic encephalomyelitis (EAE), is not MS but a different demyelinating disorder, i.e. acute disseminated encephalomyelitis and acute haemorrhagic leucoencephalitis. Extrapolation of EAE research to MS has been guided largely by faith and a blind acceptance rather than sound, scientific rationale. No specific or sensitive immunological test exists that is diagnostic of MS despite the extensive application of modern technology. Immunosuppression has failed to have any consistent effect on prognosis or disease progression. The available data on MS immunotherapy are conflicting, at times contradictory and are based on findings in animals with EAE. They show predominantly a 30% effect in relapsing/remitting MS which suggests powerful placebo effect. Critical analysis of the epidemiological data shows no association with any specific autoimmune diseases, but does suggest that geographic factors and age at development posit an early onset possibly dependent on environmental influences. Certain neurological diseases are, however, found in association with MS, namely hypertrophic peripheral neuropathy, neurofibromatosis-1, cerebral glioma, glioblastoma multiforme and certain familial forms of narcolepsy. These share a common genetic influence possibly from genes on chromosome 17 affecting cell proliferation. A significant number of these disorders are of neural crest origin, the classical example being abnormalities of the Schwann cell. These and other data allow us to propose that MS is a developmental neural crest disorder, i.e. a cristopathy, implicating glial cell dysfunction with diffuse blood-brain barrier breakdown. The data on transcription factor SOX10 mutations in animals may explain these bizarre clinical associations with MS and the phenotypic variability of such alterations (Cossais et al. 2010). Research directed to the area of neural crest associations is likely to be rewarding.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 2 3%
Iran, Islamic Republic of 1 1%
Unknown 65 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 22%
Student > Ph. D. Student 10 15%
Student > Bachelor 8 12%
Student > Master 7 10%
Professor > Associate Professor 3 4%
Other 7 10%
Unknown 18 26%
Readers by discipline Count As %
Medicine and Dentistry 20 29%
Agricultural and Biological Sciences 9 13%
Neuroscience 5 7%
Nursing and Health Professions 3 4%
Biochemistry, Genetics and Molecular Biology 2 3%
Other 10 15%
Unknown 19 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 December 2023.
All research outputs
#2,583,139
of 22,649,029 outputs
Outputs from Inflammopharmacology
#53
of 530 outputs
Outputs of similar age
#10,556
of 96,997 outputs
Outputs of similar age from Inflammopharmacology
#2
of 5 outputs
Altmetric has tracked 22,649,029 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 530 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 96,997 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.